Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)

Dong Hyun Kim, Sang Wook Son, Ki Heon Jeong, Jiyoung Ahn, Eun So Lee, Il-Hwan Kim, Un Ha Lee, Hai Jin Park, Joo Yeon Ko, Byung Soo Kim, Jin Ju Kim, Javed Rashid, Kwang Joong Kim

Research output: Contribution to journalArticlepeer-review


Background: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations. Objective: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis. Methods: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM. Results: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00~80.00) and 12.40 (range 2.70~39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (p=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted. Conclusion: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number ( NCT03099083).

Original languageEnglish
Article numbere21
JournalAnnals of Dermatology
Publication statusPublished - 2023
Externally publishedYes

Bibliographical note

Funding Information:
Medical writing and editorial assistance was provided by Meditech Media, and funded by AbbVie, Inc.

Funding Information:
This study was funded by AbbVie, Inc. AbbVie, Inc. was responsible for the study design and data interpretation, and has reviewed and approved this manuscript for submission.

Publisher Copyright:
Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology


  • Adalimumab
  • Health-related quality of life
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)'. Together they form a unique fingerprint.

Cite this